Do you have the same question? Follow this Question
Oct 23, 2025 - 11:05 AM
We’ve provided several answers to questions related to Cagrilintide , see some other helpful Q&A related to this product.
Question: What are the side effects of cagrilintide peptide?
Answer: Cagrilintide peptide may cause side effects such as nausea, vomiting, decreased appetite, and constipation. Some people may also experience injection site reactions or gastrointestinal discomfort. Serious side effects are rare but can include severe allergic reactions.
Question: Is this product being studied in combination with other drugs?
Answer: Yes, it is being studied in combination with semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, under the investigational name CagriSema. Combining therapies can enhance weight loss effects and provide more comprehensive metabolic management.
Question: Is this product being studied as a single therapy?
Answer: Yes, it is being investigated as monotherapy, meaning it can be used alone. Monotherapy provides a simpler option for patients who may not tolerate combination treatments.
Question: What is the pH of the formulation?
Answer: The formulation is adjusted to a pH of approximately 4.0. A stable pH ensures product integrity and reduces injection site irritation.
Question: What buffer agents are included in the formulation?
Answer: The formulation may include glutamic acid/glutamate (2–10 mM), lactic acid/lactate (2–35 mM), or acetic acid/acetate (2–10 mM) as buffer agents. Buffer agents help stabilize the solution and maintain the correct pH for injection.
Question: What is the PubChem CID for this product?
Answer: The PubChem CID is 137700278. PubChem is a database for chemical molecules, helping with research and cross-referencing.
Question: What is the DrugBank identifier for this product?
Answer: The DrugBank ID is DB16357. DrugBank is a database that provides detailed drug information, useful for researchers and healthcare providers.
Question: What is the product’s legal status?
Answer: The product is investigational and currently in Phase 3 clinical trials, meaning it is not yet approved for general use. Knowing the legal status helps users understand access limitations and safety considerations.
Question: What is the recommended maintenance dose in clinical trials?
Answer: The maintenance dose used in clinical trials is 2.4 mg weekly, typically reached by week 17 through a dose-escalation protocol. Gradual dose escalation helps minimize side effects and improve tolerability.
Question: What is the bioavailability of this product when injected under the skin?
Answer: The bioavailability is about 45% when administered subcutaneously, meaning that nearly half of the administered dose reaches the bloodstream. This is important because higher bioavailability can lead to more predictable therapeutic effects.
Question: What is the elimination half-life?
Answer: The elimination half-life is approximately 168 hours, which is equivalent to 7 days. A longer half-life allows for once-weekly dosing, making it more convenient for people managing chronic conditions.
View all Cagrilintide Questions & Answers
